{
  "id": "61f58de2882a024a1000000a",
  "type": "factoid",
  "question": "Which factor is inhibited by Milvexian?",
  "ideal_answer": "Milvexian is a small molecule, active-site inhibitor of factor XIa (FXIa) being developed to prevent and treat thrombotic events.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34558200",
    "http://www.ncbi.nlm.nih.gov/pubmed/34752670",
    "http://www.ncbi.nlm.nih.gov/pubmed/34494428",
    "http://www.ncbi.nlm.nih.gov/pubmed/34780683"
  ],
  "snippets": [
    {
      "text": "Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34494428",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34558200",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Milvexian (BMS-986177/JNJ-70033093) is a small molecule, active-site inhibitor of factor XIa (FXIa) being developed to prevent and treat thrombotic events. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34558200",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Additional data are needed regarding the efficacy and safety of milvexian, an oral factor XIa inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34780683",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Postoperative factor XIa inhibition with oral milvexian in patients undergoing knee arthroplasty was effective for the prevention of venous thromboembolism and was associated with a low risk of bleeding.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34780683",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SIONS: Postoperative factor XIa inhibition with oral milvexian in patients undergoing knee arthroplasty was effective for the prevention of venous thromboembolism and was associated with a low risk of bleeding. (Fund",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34780683",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Milvexian (BMS-986177/JNJ-70033093) is an orally bioavailable factor XIa (FXIa) inhibitor currently in phase 2\u00a0clinical trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34752670",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "S: Milvexian is an active-site, reversible inhibitor of human and rabbit FXIa (Ki 0.11 and 0.38\u00a0nM, respectively). Milvexian increased activat",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34752670",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34752670",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Milvexian (BMS-986177/JNJ-70033093) is a small molecule, active-site inhibitor of factor XIa (FXIa) being developed to prevent and treat thrombotic events. The",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34558200",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Milvexian (BMS-986177/JNJ-70033093) is an orally bioavailable factor XIa (FXIa) inhibitor currently in phase 2\u00a0clinica",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34752670",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Milvexian (BMS-986177/JNJ-70033093) is a small molecule, active-site inhibitor of factor XIa (FXIa) being developed to prevent and treat thrombotic events.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34558200",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Milvexian (BMS-986177/JNJ-70033093) is an orally bioavailable factor XIa (FXIa) inhibitor currently in phase 2\u00a0clinical trials.OBJECTIVES: To evaluate in vitro properties and in vivo characteristics of milvexian.METHODS: In vitro properties of milvexian were evaluated with coagulation and enzyme assays, and in vivo profiles were characterized with rabbit models of electrolytic-induced carotid arterial thrombosis and cuticle bleeding time (BT).RESULTS: Milvexian is an active-site, reversible inhibitor of human and rabbit",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34752670",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "coagulants. Additional data are needed regarding the efficacy and safety of milvexian, an oral factor XIa inhibitor.METHODS: In this parallel-group, phase 2 trial, we randomly assigned 1242 patients undergoing knee arthroplasty to receive one of seven postoperative regimens of milvexian (25 mg, 50 mg, 100 mg, or 200 mg twice daily or 25 mg, 50 mg, or 200 mg once daily) or enoxapari",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34780683",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "emostasis, even when combined with aspirin in rabbits. This study supports inhibition of FXIa with milvexian as a promising",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34752670",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "k of 30% (one-sided P<0.001). Bleeding of any severity occurred in 38 of 923 patients (4%) taking milvexian and in 12 of 296 patients (4%) taking enoxaparin; major or clinically relevant nonmajor bleeding occurred in 1% and 2%, respectively; and serious adverse events were reported in 2% and 4%, respectively.CONCLUSIONS: Postoperative factor XIa inhibition with oral milvexian in patients undergoing knee arthroplasty was effective for the prevention of venous thromboembolism and ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34780683",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "XIa"
}